New phase-III clinical trials showed that combining immune checkpoint inhibitors – atezolizumab (1), pembrolizumab (2), or durvalumab (3) – with cytotoxic chemotherapy improves the treatment efficacy in patients with different types of lung cancer. These trials therefore confirm that enhancing tumor-specific T-cell immunity by inhibiting programmed death-ligand 1 or programmed death-1 signaling is promising in the treatment of lung cancer, which is one of the most frequent cancer types.

In the United States, over 1.7 million new cancer cases and more than 600,000 cancer deaths were reported in 2018 (4). During the past decade, the incidence rate in women was stable and in men it declined by approximately 2% annually, while the death rate declined by about 1.5% annually (4). Similar patterns were observed in Croatia (5). These substantial achievements can be attributed to the development of new technologies and anti-cancer agents, as well as early diagnosis, advanced treatment, and overall prevention. However, there are still large inequalities, which may be linked not only to limited access to high-quality health care but also to unhealthy lifestyle. Potentially modifiable risk factors, including chronic diseases, are now confirmed to highly associate with cancer risk (6,7). Of course, there are also non-modifiable risk factors, such as sex, age, and family history.

Strong evidence shows that cancer incidence can be decreased by adhering to a healthy lifestyle. Higher coffee consumption was associated with a lower risk of death from various causes (8,9), whereas hot tea consumption was associated with an increased risk for esophageal cancer (10), especially when combined with related risk factors, such as excessive alcohol or tobacco use. Other behavioral risk factors include housing and food insecurity, e-cigarettes use, consumption of ultra-processed foods, toxins exposure, health care access, and health status.

Current status of cancer in the world calls for new strategies and measures for cancer control and prevention. The author of this text previously developed one such strategy (11), ie, intervention of RT-ABCDEF (iRT-ABCDEF), meaning “follow-up, examination, disease and risk factor control, changing unhealthy lifestyle and cutting spreading pathways, biohazard control, and antagonistic treatment” as an intervention of routine, right, and reversible treatment (iRT) (Table 1). Similar to the magic and novel “polypill” (SEEDi1.5) (12), which is based on five core healthy elements “environment-sleep-emotion-exercise-diet,” it is an effective strategy for prevention and control of major non-communicable diseases (mNCDs), suitable not only for CVD but also for cancer and diabetes. For example, physical activity is a simple way to reduce the cancer risk associated with chronic diseases (7). In fact, many chronic diseases result from unhealthy lifestyle, such as exposure to air pollution, noises, staying up late, long term depression, lack of physical activity or obesity, heavy drinking or smoking, and diets with high salt, sugar, and lipid intake and low vegetables and fruits intake. Both basic and clinical studies in recent years have shown that associations among diet, gut microbiome, and human immunity lead to cancer and affect anticancer treatment (13,14).

Measures such as smoking ban and laws on air pollution are important because grade-zero prevention plays a key role in fighting cancer. It is time to enhance public knowl-
TABLE 1. iRT-ABCDEF as a standardized comprehensive program for cancer

| iRT-ABCDEF | Tips |
|------------|------|
| F | Follow-up, especially of patients with family history, precancerous lesions, and unhealthy lifestyle for primary and secondary prevention, tracking outcome, and evaluating drug, surgical, or radiotherapy effects. It is very important for large-scale epidemiology investigations. |
| E | Examination for early diagnosis, treatment, and primary and secondary prevention, which includes large-scale screening and regular comprehensive or targeted physical examination, such as testing for biomarkers (eg, AFP, CEA, PSA, CA 125, CA 19-9, CA 15-3) and genetic variants (eg, BRCA1 and BRCA2), gastroscopy, colonoscopy, molybdenum photography, echocardiography, biopsy, immunohistochemical or histopathologic analysis, computed tomography and single photon emission computed tomography, and magnetic resonance imaging. |
| D | Disease and risk factor control, including family history, diabetes, chronic infection (HP, CMV, EBV, HPV), chronic hepatitis, gastritis or ulcer, intestinal or gallbladder polyps, heavy drinking or smoking, physical inactivity, and obesity. |
| C | Change unhealthy lifestyle and cut spreading pathways by SEEDi1.5 or SEEDi3.0 strategies, such as cessation of smoking or drinking, and cutting spreading or genetic pathways by isolation of patients, and gene knockout or gene editing technologies. |
| B | Biohazard control, including control of abnormal symptoms and signs, abnormal physiological indexes and biomarker level, precancerous lesions, family history, unhealthy lifestyle, high-risk occupation, and early tumor metastasis and recurrence. Grade-zero prevention based on “Health in All Policies and Laws” is a good choice. |
| A | Antagonistic treatment, including chemical agents, such as statin-based treatment, precision radiotherapy, immunotherapy with checkpoint inhibition, cancer vaccine, and other new methods. Sometimes, traditional Chinese medicine is also a good choice for cancer treatment. |
| IRT | Intervention with above strategies as routine, right, and reversible treatment |

*AFP – alpha-fetoprotein; CEA – carcinoembryonic antigen; PSA – prostate-specific antigen; CA – cancer antigen; HP – Helicobacter pylori; CMV – cytomegalovirus; EBV – Epstein-Barr virus; HPV – human papillomavirus.
†SEEDi1.5 strategies were developed based on five core healthy elements, that is, external and internal environment, sleep, emotion, exercise, and diet intervention (EleSEEDi). When EleSEEDi-based lifestyle is combined with iRT-ABCDEF and Grade 210 prevention, it is 3.0 version of SEEDi strategy (SEEDi3.0).

References

1. Horn L, Mansfield AS, Szczęsna A, Havel L, Kراكowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9. Medline:30280641 doi:10.1056/NEJMoa1809064
2. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040-51. Medline:30280635 doi:10.1056/NEJMoa1809679
3. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-50. Medline:30280658 doi:10.1056/NEJMoa1810865
4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018;68:7-30. Medline:2913949 doi:10.3322/caac.21442
5. Siroglović KJ, Polič Vižintin M, Tripković I, Šekerića M, Kukolj S. Trends in incidence of lung cancer in Croatia from 2001 to 2013: gender and regional differences. Croat Med J. 2017;58:358-363. Medline:29094814 doi:10.3322/cmj.2017.58.358
6. Islami F, Godin Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54. Medline:29160902 doi:10.3322/caac.21440
7 Tu H, Wen CP, Tsai SP, Chou WH, Wen C, Ye Y, et al. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ. 2018;360:k134. Medline:29386192 doi:10.1136/bmj.k134
8 Gunter MJ, Murphy N, Cross AJ, Dossus L, Dartois L, Fagherazzi G, et al. coffee drinking and mortality in 10 European countries: a multinational cohort study. Ann Intern Med. 2017;167:236-47. Medline:28693038 doi:10.7326/M16-2945
9 Park SY, Freedman ND, Haiman CA, Le Marchand L, Wilkens LR, Setiawan VW. association of coffee consumption with total and cause-specific mortality among nonwhite populations. Ann Intern Med. 2017;167:228-35. Medline:28693036 doi:10.7326/M16-2472
10 Yu C, Tang H, Guo Y, Bian Z, Yang L, Chen Y, et al. Effect of hot tea consumption and its interactions with alcohol and tobacco use on the risk for esophageal cancer: a population-based cohort study. Ann Intern Med. 2018;168:489-97. Medline:29404576 doi:10.7326/M17-2000
11 Hu CS. RT-AbCDE strategy for management and prevention of human diseases. Chin J Integr Med. 2008;14:147-50. Medline:18219448 doi:10.1007/s11655-007-9009-z
12 Hu C. Grants supporting research in China. Eur Heart J. 2018;39:2342-4. Medline:30052949 doi:10.1093/eurheartj/ehy293
13 Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65-74. Medline:27383981 doi:10.1038/nature18847
14 Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, et al. The maternal microbiota drives early postnatal innate immune development. Science. 2016;351:1296-302. Medline:26989247 doi:10.1126/science.aad2571
15 Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA. 2018;319:154-64. Medline:29318276 doi:10.1001/jama.2017.19130
16 Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niklić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023-75. Medline:29395269 doi:10.1016/S0140-6736(17)33326-3
17 Markoš P, Brčić L, Brčić L, Jakić-Razumović J, Pulanić R. Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study. Croat Med J. 2018;59:100-7. Medline:29972732 doi:10.3325/cmj.2018.59.100